126 related articles for article (PubMed ID: 26432040)
1. Emerging strategies for targeting PI3K in gynecologic cancer.
Bregar AJ; Growdon WB
Gynecol Oncol; 2016 Feb; 140(2):333-44. PubMed ID: 26432040
[TBL] [Abstract][Full Text] [Related]
2. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
3. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.
Myers AP
Clin Cancer Res; 2013 Oct; 19(19):5264-74. PubMed ID: 24089439
[TBL] [Abstract][Full Text] [Related]
4. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.
Diaz-Padilla I; Duran I; Clarke BA; Oza AM
Cancer Treat Rev; 2012 Oct; 38(6):767-75. PubMed ID: 22381585
[TBL] [Abstract][Full Text] [Related]
5. A Review of mTOR Pathway Inhibitors in Gynecologic Cancer.
de Melo AC; Paulino E; Garces ÁH
Oxid Med Cell Longev; 2017; 2017():4809751. PubMed ID: 28286604
[TBL] [Abstract][Full Text] [Related]
6. Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies.
Eskander RN; Tewari KS
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):847-58. PubMed ID: 25301678
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
8. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
9. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
10. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Wang X; Ding J; Meng LH
Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
[TBL] [Abstract][Full Text] [Related]
11. PI3K pathway in gynecologic malignancies.
Salvesen HB; Werner HM; Krakstad C
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714506
[TBL] [Abstract][Full Text] [Related]
12. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
13. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
Coughlin CM; Johnston DS; Strahs A; Burczynski ME; Bacus S; Hill J; Feingold JM; Zacharchuk C; Berkenblit A
Breast Cancer Res Treat; 2010 Nov; 124(1):1-11. PubMed ID: 20803067
[TBL] [Abstract][Full Text] [Related]
14. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
Britten CD
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1395-409. PubMed ID: 23443307
[TBL] [Abstract][Full Text] [Related]
15. Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.
Leroy C; Amante RJ; Bentires-Alj M
Biochem Soc Trans; 2014 Aug; 42(4):733-41. PubMed ID: 25109950
[TBL] [Abstract][Full Text] [Related]
16. PI3 kinase inhibitors in the clinic: an update.
Kurtz JE; Ray-Coquard I
Anticancer Res; 2012 Jul; 32(7):2463-70. PubMed ID: 22753702
[TBL] [Abstract][Full Text] [Related]
17. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
18. Detection of PI3K inhibition in human neuroblastoma using multiplex luminex bead immunoassay: a targeted approach for pathway analysis.
Lang WH; Sandoval JA
J Biomol Screen; 2014 Oct; 19(9):1235-45. PubMed ID: 25092063
[TBL] [Abstract][Full Text] [Related]
19. PI3K: a potential therapeutic target for cancer.
Chen Y; Wang BC; Xiao Y
J Cell Physiol; 2012 Jul; 227(7):2818-21. PubMed ID: 21938729
[TBL] [Abstract][Full Text] [Related]
20. Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
Zhang J; Roberts TM; Shivdasani RA
Gastroenterology; 2011 Jul; 141(1):50-61. PubMed ID: 21723986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]